Agile 3+
Identification of advanced fibrosis in MASLD patients
Learn more
Fast Target
Current MASH drug developments focus on patients with MASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic MASH (MASH + NAS≥4 + F≥2).
Fast Construction
Fast combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-MASH, at the point-of-care, reducing invasive and costly procedures.
Fast Performance
Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).
Several publications advocate the use of Fast.
Download myFibroScan to get Fast
Fast is a FibroScan®-based score available on the free application myFibroScan.
Fast: tried and trusted
Improvements in Fast are consistent with amelioration of key histologic features of MASH, including both inflammation and fibrosis.
Fast score demonstrated good discrimination for fibrotic MASH in our cohort.
I believe that Fast is a key element for MASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.
All our solutions come with a dedicated support
From installation, to training and local support, we provide you with the highest quality of services.
Fast is an algorithm intended to aid in the diagnosis of active fibrotic Non-Alcoholic Steatohepatitis (NASH) in patients with suspected Non-Alcoholic Fatty Liver Disease (NAFLD). Fast is used, during liver assessment, in patient with suspected NAFLD. Fast is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and healthcare issues, it is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions. The following precautions must be observed when using Fast: LSM (also known as E) and CAP measurements must come from the same FibroScan® examination; There must be no more than 6 months between the FibroScan® examination and the blood sample necessary for AST assessment. Fast must not be used in the following situations : pregnancy, patients under 18 years old, chronic or acute liver diseases other than NAFLD, liver transplant patients, cardiac failure and/or significant vascular disease, confirmed diagnosis of active malignancy or other terminal disease, use of treatment inducing liver injury.
*MASLD/MASH is formerly knowed as NAFLD/NASH
To access the Fast User Guides, connect to myfibroscan.com:
Scores > Fast > Learn more
Our liver health solutions
Agile 4
Identification of cirrhosis in patients with MASLD
Learn more
Liver Health Management
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Learn more
FibroScan® by echosens
The non-invasive gold standard solution for comprehensive management of liver health
Learn more
